Medical Condition News

RSS

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

A protein long thought to be a secondary regulator in the heart's response to stressors like hypertension actually appears to be a primary regulator according to researchers from the Center for Translational Medicine at Thomas Jefferson University.

17 Nov 2009

Sudden cardiac death more predictable in men than women

A woman who suffers sudden cardiac arrest is significantly less likely than a man to exhibit the decrease in the heart's pumping ability that is widely recognized as a precursor, says a new study in the Nov. 24 Journal of the American College of Cardiology.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

17 Nov 2009

New guidebook on how to manage bipolar symptoms

Many Americans suffer from bipolar disorder and their treatment often includes myriad medications. But what if there is another way to cope with the illness that comes from within? In his revolutionary new guidebook, "Living Out of Darkness: A personal journey of embracing the bipolar opportunity" (published by AuthorHouse), George Denslow -- who was diagnosed bipolar at age 17 -- presents a comprehensive, in-depth look at how to manage bipolar symptoms using a technique he calls "unmedicated spiritual engagement."

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS).

16 Nov 2009

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study will be published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).

16 Nov 2009

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.

16 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Migraine headaches linked with increased risk of common kind of stroke

Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Gentium to present Defibrotide trial data at the ASH meeting

Gentium S.p.A. announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.

16 Nov 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

Medical Condition News

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

Sudden cardiac death more predictable in men than women

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

New guidebook on how to manage bipolar symptoms

Stem cell therapy to treat heart, lung and vascular diseases show positive results

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Migraine headaches linked with increased risk of common kind of stroke

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Gentium to present Defibrotide trial data at the ASH meeting

Erbitux recognized as one of the major clinical cancer advances of 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Positive results from Winston Laboratories' Civamide Patch trial

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Myeloma UK launches innovative clinical trial network

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News